

S 3466

Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 12, 2020

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Mar 12, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/3466>

Sponsor

Name: Sen. McSally, Martha [R-AZ]

Party: Republican • **State:** AZ • **Chamber:** Senate

Cosponsors (1 total)

| Cosponsor | Party / State | Role | Date Joined |
|-------------------------|---------------|------|--------------|
| Sen. Jones, Doug [D-AL] | D · AL | | Mar 12, 2020 |

Committee Activity

| Committee | Chamber | Activity | Date |
|-------------------|---------|-------------|--------------|
| Finance Committee | Senate | Referred To | Mar 12, 2020 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

| Bill | Relationship | Last Action |
|-------------|--------------|--|
| 116 HR 4597 | Related bill | Oct 2, 2019: Referred to the Subcommittee on Health. |

Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020 or the ACCESS for Biosimilars Act of 2020

This bill temporarily eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations.

The bill's provisions apply to products that are furnished during the five-year period beginning on January 1, 2021, or the date on which the product is first marketed, whichever is later.

Actions Timeline

- **Mar 12, 2020:** Introduced in Senate
- **Mar 12, 2020:** Read twice and referred to the Committee on Finance.